PRISM Registry: Pseudobulbar Affect Registry Series
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress has been made in better understanding this debilitating condition, but much more needs to be done. That's why a new PBA patient registry, PRISM (Pseudobulbar Affect RegIstry Series), has been initiated.
The goal of PRISM is to establish the prevalence and quality of life (QOL) impact of PBA in patients with underlying neurologic conditions including
- Alzheimer's disease
- Amyotrophic lateral sclerosis
- Multiple sclerosis
- Parkinson's disease
- Stroke
- Traumatic brain injury
Because this is an observational registry, it doesn't require you to intervene with any specific treatment or procedure. Your participation allows the PRISM registry to collect and analyze data from your site and also compare it to national numbers captured in the PRISM registry about PBA across all of the major at-risk neurologic populations.
| Condition |
|---|
|
Alzheimer's Disease Amyotrophic Lateral Sclerosis (ALS) Multiple Sclerosis (MS) Parkinson's Disease Stroke Traumatic Brain Injury |
| Study Type: | Observational |
| Official Title: | PRISM Registry: Pseudobulbar Affect Registry Series |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
The population for this study will be 18 years and over
Inclusion Criteria:
- All participants must have underlying neurologic conditions known to be risk factors of PBA: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's Disease, Stroke, and Traumatic Brain Injury.
- The population for this study will be 18 years and over
Contacts and Locations| Contact: Randall Kaye, MD | 1-855-472-2722 |
| United States, California | |
| Avanir Pharmaceuticals | Recruiting |
| Aliso Viejo, California, United States, 92656 | |
| Contact: Randall Kaye, MD 855-472-2722 | |
| Study Chair: | Randall Kaye, MD | Avanir Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Randall Kaye, MD, Chief Medical Officer, Avanir Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01366027 History of Changes |
| Other Study ID Numbers: | 11-AVR-REG-001 |
| Study First Received: | June 2, 2011 |
| Last Updated: | June 2, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Avanir Pharmaceuticals:
|
pseudobulbar affect |
Additional relevant MeSH terms:
|
Alzheimer Disease Amyotrophic Lateral Sclerosis Multiple Sclerosis Parkinson Disease Sclerosis Stroke Motor Neuron Disease Brain Injuries Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders |
Mental Disorders Spinal Cord Diseases TDP-43 Proteinopathies Neuromuscular Diseases Proteostasis Deficiencies Metabolic Diseases Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Demyelinating Diseases Autoimmune Diseases Immune System Diseases Parkinsonian Disorders Basal Ganglia Diseases Movement Disorders Pathologic Processes |
ClinicalTrials.gov processed this record on June 18, 2013